Literature DB >> 20405270

Soluble HLA-G induces NF-kappaB activation in natural killer cells.

I Zidi1, C Guillard, E D Carosella, P Moreau.   

Abstract

Human leukocyte antigen (HLA)-G is an immunomodulatory molecule discovered for the first time in the maternal-fetal interface. In cancer context, where high number of natural killer (NK) cells is described, the presence of HLA-G in its soluble form is thought to be essential for NK cells signaling. To evaluate intracellular signaling in NK cells upon HLA-G soluble forms stimulation, we investigate the role of soluble HLA-G (HLA-G5- and HLA-G1 shedding form) stimulation on classical nuclear factor (NF)-kappaB pathway activation. We reported that these two forms of soluble HLA-G could activate NF-kappaB in NK cells. NF-kappaB activation in NK cells does implicate neither phosphatidylinositol 3-kinase (PI3K) nor MEK (MAP kinase kinase) as demonstrated after specific inhibition experiments. We demonstrated elsewhere that NF-kappaB activation in NK cells is not implicated in cytotoxicity inhibition by HLA-G. Our findings may suggest the important role played by NF-kappaB activation after soluble HLA-G stimulation in other NK cells function.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20405270     DOI: 10.1007/s13105-010-0005-y

Source DB:  PubMed          Journal:  J Physiol Biochem        ISSN: 1138-7548            Impact factor:   4.158


  40 in total

1.  HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes.

Authors:  F A Le Gal; B Riteau; C Sedlik; I Khalil-Daher; C Menier; J Dausset; J G Guillet; E D Carosella; N Rouas-Freiss
Journal:  Int Immunol       Date:  1999-08       Impact factor: 4.823

2.  Interaction of NF-kappaB and NFAT with the interferon-gamma promoter.

Authors:  A Sica; L Dorman; V Viggiano; M Cippitelli; P Ghosh; N Rice; H A Young
Journal:  J Biol Chem       Date:  1997-11-28       Impact factor: 5.157

3.  Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy.

Authors:  S Ugurel; V Rebmann; S Ferrone; W Tilgen; H Grosse-Wilde; U Reinhold
Journal:  Cancer       Date:  2001-07-15       Impact factor: 6.860

4.  Residues Met76 and Gln79 in HLA-G alpha1 domain involve in KIR2DL4 recognition.

Authors:  Wei Hua Yan; Li An Fan
Journal:  Cell Res       Date:  2005-03       Impact factor: 25.617

5.  p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor.

Authors:  W Vanden Berghe; S Plaisance; E Boone; K De Bosscher; M L Schmitz; W Fiers; G Haegeman
Journal:  J Biol Chem       Date:  1998-02-06       Impact factor: 5.157

6.  Increase in HLA-G1 proteolytic shedding by tumor cells: a regulatory pathway controlled by NF-kappaB inducers.

Authors:  I Zidi; C Guillard; C Marcou; I Krawice-Radanne; D Sangrouber; N Rouas-Freiss; E D Carosella; P Moreau
Journal:  Cell Mol Life Sci       Date:  2006-11       Impact factor: 9.261

7.  Alloreactive CD4+ and CD8+ T cells express the immunotolerant HLA-G molecule in mixed lymphocyte reactions: in vivo implications in transplanted patients.

Authors:  Solène Le Rond; Joël Le Maoult; Caroline Créput; Catherine Menier; Marina Deschamps; Gaëlle Le Friec; Laurence Amiot; Antoine Durrbach; Jean Dausset; Edgardo D Carosella; Nathalie Rouas-Freiss
Journal:  Eur J Immunol       Date:  2004-03       Impact factor: 5.532

Review 8.  NK cell-based cancer immunotherapy.

Authors:  John Stagg; Mark J Smyth
Journal:  Drug News Perspect       Date:  2007-04

9.  Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis.

Authors:  Gyu Man Park; Sunray Lee; Boyoun Park; Eunkyung Kim; Jinwook Shin; Kwangmin Cho; Kwangseog Ahn
Journal:  Biochem Biophys Res Commun       Date:  2004-01-16       Impact factor: 3.575

10.  A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells.

Authors:  M Colonna; F Navarro; T Bellón; M Llano; P García; J Samaridis; L Angman; M Cella; M López-Botet
Journal:  J Exp Med       Date:  1997-12-01       Impact factor: 14.307

View more
  2 in total

1.  Alternative spliced CD1d transcripts in human bronchial epithelial cells.

Authors:  Kambez Hajipouran Benam; Wai Ling Kok; Andrew J McMichael; Ling-Pei Ho
Journal:  PLoS One       Date:  2011-08-11       Impact factor: 3.240

2.  Co-expression of ILT4/HLA-G in human non-small cell lung cancer correlates with poor prognosis and ILT4-HLA-G interaction activates ERK signaling.

Authors:  Yanwen Zhang; Jianqiang Zhao; Lijun Qiu; Pei Zhang; Juan Li; Dong Yang; Xiaojuan Wei; Yali Han; Siyue Nie; Yuping Sun
Journal:  Tumour Biol       Date:  2016-03-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.